FDA Clearance Tracker · P150038-S005
Exablate Model 4000 System
Last checked: Nov 20, 2026Latest source record: Sep 20, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Sep 20, 2018
Approved
Time to decision
212 days
Received Feb 20, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
Device type
- Device type
- MR-guided focused ultrasound system (POH)
- Device class
- Class III
- Specialty
- Neurology & Neurosurgery
FDA's approval statement
As written in FDA's record.
Approval for the Exablate 4000 Type 1.1 System, an expansion of the Exablate 4000 Type 1.0 System to add compatibility with Siemens 3T Skyra, Prisma and PrismaFIT MR systems, including hardware changes to the devices Helmet System, changes to the electronics of the devices Front End Cabinet, and changes to the device sub-systems required for connectivity with these Siemens MRI systems.
Source documents
Other decisions for Insightec
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Exablate Model 4000 Type-1 SystemPMA supplement
P150038-S037 · Decided Jul 3, 2025 · 352 days after receipt · Panel Track
Device type: MR-guided focused ultrasound system (POH) · Neurology & Neurosurgery
K231378 · Decided Oct 30, 2023 · 171 days after receipt
Device type: High Intensity Ultrasound System For Prostate Tissue Ablation (PLP) · GI, Urology & Nephrology
- Exablate Prostate System510(k)
K212150 · Decided Nov 23, 2021 · 137 days after receipt
Device type: High Intensity Ultrasound System For Prostate Tissue Ablation (PLP) · GI, Urology & Nephrology
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.